About a year earlier, Dutch firm AM-Pharma BV banked €29.2 million (then US$39.8 million) in a Series D round, apparently the largest venture capital financing in Dutch biotechnology thus far...The company planned to switch from a bovine to a recombinant form of its AKI treatment, alkaline phosphatase. (See BioWorld Today, Sept. 14, 2011.) Bunnik, the Netherlands-based AM-Pharma had then gained only preliminary data from two small-scale clinical trials suggesting that bovine alkaline phosphatase

Proceeds will be used to fund ACT's clinical activities, including its three ongoing Phase I/II trials for forms of macular degeneration, for development of its other clinical activities and for general corporate purposes...Horizon Pharma Inc., of Deerfield, Ill., priced an underwritten public offering of 21.42 million units, with each unit consisting of one share of its common stock and a warrant to purchase a half share of its common stock...Royalty Pharma has invested $25 million under its royalty

The warrants have an exercise price of $3.22 and an expiration date of Dec. 15, 2015...Gemmus Pharma Inc., of San Francisco, closed a Series A round to advance its host-targeted treatment for influenza

If this pivotal preclinical study pans out, we'll try to move into human clinical trials as soon as feasible," Marshall said...miRagen's compounds were developed under a 2010 partnership deal with Santaris Pharma A/S using its Locked Nucleic Acid (LNA) platform...Rodman & Renshaw LLC acted as exclusive placement agent.

The exercise price was $2.96 per share, generating gross proceeds of approximately $12.4 million...The new warrants have a three-year term and an exercise price of $4.05 per share, the closing price of Corcept's shares on March 23

But starting this year, the big pharma firm is shouldering three-fourths of the financial burden...The investor also will receive 50 percent warrant coverage at an exercise price of $0.286 per share

Stamford, Conn.-based Purdue Pharma LP's extended-release hydromorphone product Palladone was voluntarily removed from the market in July 2005 less than a year after approval because of a high occurrence of unintentional "dose-dumping" – when opioids are accidentally or intentionally crushed or dissolved, resulting in the active ingredient being rapidly released into the bloodstream, often causing a euphoric high...is an immediate-release version, which is sold by Purdue Pharma as Dilaudid...Net

Horizon Pharma Inc., of Northbrook, Ill., set terms for its proposed initial public offering...The specialty pharma firm is aiming to sell 5.5 million shares priced between $10 and $12 each...Proceeds will be used for clinical trials and general purposes

Series B warrants to purchase as many as 4 million shares of common stock at an exercise price of 75 cents per share for between eight and 19 months...OncoSec said it intends to use proceeds from the offering for further development of its ElectroOncology therapies to treat cancers, for clinical studies and for general corporate purposes.

Staff Writer Tranzyme Pharma Inc., of Durham, N.C., filed for a proposed $75 million initial public offering to support clinical development of product candidates ulimorelin and TZP-102 for the treatment of acute (hospital-based) and chronic gastrointestinal motility disorders...The company said it is focused on two key ion channel targets against which it has already developed a pipeline of compounds that are in clinical and pre-clinical development.

VeriStrat is designed to predict response to targeted therapy Tarceva (erlotinib, Astellas Pharma Inc. and Roche AG...Proceeds will support clinical trials of BiondVax's flu vaccine and manufacturing upgrades...The company sold 4.2 million units for C$1.11 apiece, with each unit consisting of one common share and one warrant to purchase an additional share with an exercise price of C$1.33

Staff Writer Noxxon Pharma AG has concluded a $2 million financing, as part of a $35 million Series D financing that will fund development of its three development programs to proof of concept...The first-in-human clinical trial for NOX-A12 was successfully completed in May in healthy individuals following intravenous administration of the drug candidate...The offering includes 4.375 million shares of common stock at a per share purchase price of $1.20 and four year warrants to purchase 2.625 million

Bioniche Pharma's lead product Urocidin for bladder cancer is currently in clinical trials. (See BioWorld Today, July 16, 2010.)

raised $25 million in Series B financing to advance its preclinical RNAi oncology program into clinical trials...Going forward, Dicerna will use the $25 million Series B financing to support clinical studies of its oncology therapeutics, and will rely on further nondilutive funding from pharma partners to develop and mature its technology

If approved, JZP-6 is slated to go up against big pharma players Pfizer Inc., of New York, which markets Lyrica (pregabalin) and Indianapolis-based Lilly, which sells Cymbalta (duloxetine hydrochloride...A portion of the funds might also be used to start clinical trials for new indications for lead product Hextend, including severe malaria...Funds will be used for working capital needs, including the ongoing clinical development of MN-221 in acute exacerbations of asthma and chronic obstructive

AspenBio Pharma Inc., of Castle Rock, Colo., entered definitive agreements with certain new and existing institutional investors to sell an aggregate of about 2.4 million units, each consisting of one share of common stock and one warrant to purchase 0.285 shares of stock, for gross proceeds of about $10 million...Investors agreed to purchase the units for a negotiated price of $4.15 per unit, and the per-share exercise price of the warrants is $4.82, exercisable beginning on the date of closing of

The warrants have an exercise price of $0.6029 per warrant share, for total potential additional proceeds of approximately $12 million...NovaDel Pharma Inc., of Bridgewater, N.J., entered a purchase agreement to raise approximately $1.5 million through the sale of 9 million shares of its common stock to institutional investors at a price of $0.165 per share

Proceeds will support clinical trials of nanobodies for thrombosis, osteoporosis, inflammation and cancer...Genticel S/A (formerly BT Pharma S/A), of Toulouse, France, raised €13.1 million (US$17.7 million) in private equity to conduct a Phase I trial with ProCervix, a vaccine to prevent cervical cancer in women already infected with human papillomavirus...The company is selling 7.1 million shares priced at about 75 cents each plus warrants to purchase another 3.55 million shares with an exercise

In exchange, the company agreed to issue each investor 2 million shares of stock priced at 25 cents each and 1 million warrants with an exercise price of 50 cents per share...Cardiome Pharma Corp., of Vancouver, British Columbia, drew down $25 million from a $100 million credit facility provided by Merck & Co...Proceeds will support clinical trials of FP-01, a synthetic, thermostable universal flu vaccine